Tempus AI: Deep Dive of Nancy's new pick

Tempus AI (NASDAQ: TEM) is making waves in the healthcare industry by harnessing the power of artificial intelligence (AI) to revolutionize patient care. Founded in 2015 by Eric Lefkofsky, a renowned tech entrepreneur, Tempus aims to personalize treatment by collecting and analyzing vast amounts of clinical and molecular data at scale. This comprehensive analysis delves deep into Tempus AI's operations, recent developments, financial performance, and stock potential, providing investors with valuable insights to make informed decisions.

Company Overview

Tempus AI's mission is to "unlock the power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare." 1 The company has developed an AI-driven precision medicine platform that gathers and analyzes a wide range of data, including:

Molecular data: DNA, RNA, and protein information.

Clinical data: Patient medical records, treatment history, and outcomes.

Pathology data: Tissue samples and imaging.

Radiology data: Medical images like X-rays and CT scans.

Genomic data: Complete genetic makeup of individuals.

By integrating these diverse data sources, Tempus creates a comprehensive picture of a patient's health, enabling physicians to make more informed treatment decisions and improve patient outcomes2. Furthermore, Tempus contributes to global health initiatives by analyzing data at scale to track disease outbreaks, monitor public health trends, and inform policy decisions. This real-time insight into population health supports efforts to address global health challenges more effectively3.

Products and Services

Tempus offers a diverse portfolio of products and services designed to support precision medicine across various disease areas:

xT CDx: This FDA-approved next-generation sequencing test is a comprehensive tool for solid tumor profiling. It analyzes 648 genes, including microsatellite instability status, and provides companion diagnostic claims for colorectal cancer patients. By providing a detailed genomic analysis of the tumor, xT CDx assists oncologists in making more informed treatment decisions4.

xH: Currently available for research purposes, xH is a whole-genome sequencing test designed for hematological cancer patients. This test provides a comprehensive analysis of the patient's entire genome, enabling researchers to gain a deeper understanding of the genetic factors driving the disease5.

Tempus One: This generative AI assistant empowers both physicians and researchers with AI-enabled services. In the clinic, Tempus One provides decision support, helping physicians make more informed treatment choices. It also advances research by facilitating the development of new drugs and therapies6.

Immune Profile Score: This algorithmic test helps predict a patient's response to immunotherapy, a type of cancer treatment that harnesses the body's immune system to fight cancer cells. By predicting the likelihood of a patient benefiting from immunotherapy, the Immune Profile Score helps oncologists personalize treatment plans and improve patient outcomes7.

These products and services demonstrate Tempus's commitment to innovation and its focus on developing cutting-edge tools for precision medicine.

Recent Developments and Achievements

Tempus has achieved several significant milestones in recent months, showcasing its continuous growth and dedication to advancing precision medicine through AI and data analytics:

National launch of xT CDx: The FDA-approved xT CDx test is now available nationwide, providing oncologists with a powerful tool for solid tumor profiling4.

New GenAI capabilities in Tempus One: Tempus One now includes four new generative AI-powered capabilities: patient query, patient timelines, prior authorization, and data exploration. These capabilities enable researchers to ask complex questions and receive answers derived from Tempus's de-identified curated datasets and unstructured data, accelerating research and discovery6. Tempus One introduces new GenAI capabilities to query millions of unstructured documents for research and clinical care8.

Development of xH: Tempus is developing xH, its first whole-genome sequencing test for hematological cancer patients. This test will provide a comprehensive analysis of the patient's entire genome, enabling researchers to gain a deeper understanding of the genetic factors driving the disease5.

Collaboration with Flatiron Health: Tempus has partnered with Flatiron Health to integrate its comprehensive genomic testing directly into Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR, through the Molecular Profiling Integration. This collaboration streamlines the process of ordering and receiving genomic testing results, making it easier for oncologists to incorporate this valuable information into their treatment decisions7.

Acquisition of Ambry Genetics: Tempus has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing for inherited cancer risk. This acquisition will expand Tempus's testing capabilities and strengthen its position in the precision medicine market7.

Continued Investment in Research and Development: Tempus is actively investing in research and development to enhance its product offerings and expand into new disease areas. This commitment to innovation ensures that Tempus remains at the forefront of precision medicine7.

Funding History and Valuation

Tempus has a strong track record of attracting investment, having raised a total of $1.345 billion over 12 rounds9. Key funding milestones include:

Series G - II: In December 2020, Tempus raised an undisclosed amount in a Series G - II funding round, achieving a valuation between $7.9 billion and $8.1 billion9.

Debt Financing: In October 2022, Tempus secured $275 million in debt financing from Ares Management, further strengthening its financial position9.

IPO: In June 2024, Tempus went public on the Nasdaq Stock Market (NASDAQ: TEM), raising $410.7 million in its initial public offering (IPO)9.

As of January 17, 2025, Tempus has a market capitalization of $5.53 billion10. The company's strong financial position and continued growth trajectory make it an attractive investment opportunity.

Founders and Key Executives

Tempus was founded by Eric Lefkofsky, a successful tech entrepreneur with a proven track record of building and scaling successful companies. Lefkofsky previously co-founded Groupon, Echo Global Logistics, InnerWorkings, and Mediaocean11. He serves as Tempus's Chief Executive Officer and has been instrumental in its growth and success12.

Other key executives at Tempus include:

Ryan Fukushima: Chief Operating Officer, joined Tempus as the first employee and has played a crucial role in building the company13.

Christina Antoniou: Senior Vice President, Head of Corporate Development14.

Terron Bruner: Chief Commercial Officer14.

Ezra Cohen, MD: Chief Medical Officer of Oncology14.

Shane Colley: Chief Technology Officer14.

Tempus also boasts a strong board of directors, including industry leaders and experts in healthcare and technology12.

Competitive Landscape

The precision medicine market is a dynamic and competitive landscape, with several companies vying for market share. Tempus faces competition from established players and emerging startups. Here's a closer look at some of Tempus's key competitors:

Despite this competition, Tempus has established a strong market presence and continues to differentiate itself through its comprehensive platform, advanced AI capabilities, and focus on data-driven insights1.

Financial Performance

Tempus has demonstrated strong revenue growth in recent years, indicating its increasing market penetration and adoption of its precision medicine solutions.

In 2022, the company generated $321 million in revenue, which grew to $532 million in 2023, representing a significant year-over-year increase15.

For the three months ended March 31, 2024, Tempus reported revenue of $146 million, further demonstrating its strong growth trajectory15.

Preliminary guidance from Tempus indicates revenue growth of 24% in 202516.

For the third quarter of 2024, Tempus reported a 33% year-over-year revenue increase to $180.9 million17.

Tempus AI expects full-year 2024 revenue of approximately $700 million, reflecting a 32% growth year-over-year17.

Preliminary, unaudited results for Q4 and full year 2024 show approximate full-year revenue of $693 million, showing ~30% year-over-year growth, and Q4 revenue of $200 million, representing ~35% year-over-year growth18.

However, it's important to note that Tempus is not yet profitable. The company incurred net losses of $290 million and $214 million in 2022 and 2023, respectively15. As of March 31, 2024, Tempus had an accumulated deficit of $1.5 billion15. Despite these losses, Tempus's strong revenue growth and focus on innovation suggest that the company is well-positioned for future profitability10. The acquisition of Ambry Genetics is expected to contribute to Tempus's profitability in 2025, as Ambry Genetics has a solidly positive EBITDA16. Tempus also expects its adjusted earnings before taxes, depreciation, and amortization (EBITDA) to turn positive in 202516.

Potential Risks and Challenges

While Tempus has significant potential, investors should be aware of the following risks and challenges:

Data privacy and security: Tempus collects and analyzes vast amounts of patient data, raising concerns about privacy and security breaches. The company has robust security measures in place, but ensuring ongoing data protection is crucial in maintaining patient trust and complying with regulations3.

Accessibility and affordability: Tempus's platform may not be accessible to all healthcare providers and patients due to cost and infrastructure limitations. This could limit the company's market reach and impact its growth potential3.

Algorithmic bias: AI algorithms can be biased based on the data they are trained on, potentially leading to inaccurate or unfair results. Tempus needs to ensure that its algorithms are developed and validated using diverse and representative datasets to mitigate this risk3.

Competition: The precision medicine market is competitive, and Tempus faces challenges from established players and new entrants. The company needs to continue innovating and differentiating its offerings to maintain its competitive edge.

Regulatory environment: Changes in healthcare regulations, including those related to data privacy and AI, could impact Tempus's business operations and profitability. Tempus needs to stay abreast of evolving regulations and adapt its strategies accordingly.

Financial performance: Tempus has a history of significant losses, and its future profitability remains uncertain. Investors should carefully monitor the company's financial performance and assess its path to profitability19.

Dependence on data access: Tempus's business model relies on access to and monetization of de-identified patient data, which could be affected by regulatory changes or privacy concerns. Any restrictions on data access could significantly impact the company's operations19.

Limited operating history and rapid growth: As a relatively young company, Tempus has a limited operating history, and its ability to manage its rapid growth effectively presents challenges19.

Changing Medicare rates: Fluctuations in Medicare reimbursement rates could impact Tempus's revenue and profitability, particularly for its diagnostic testing services20.

Evolving AI regulations: The regulatory landscape for AI in healthcare is constantly evolving, and new regulations could impose limitations or require modifications to Tempus's AI-powered products and services20.

Investors should carefully consider these risks before investing in Tempus AI stock.

Stock Analysis

Tempus AI (NASDAQ: TEM) stock has experienced significant volatility since its IPO in June 2024. After initially surging, the stock price has pulled back in recent months16. As of January 17, 2025, the stock price is $35.1510.

Analyst ratings for Tempus AI stock are generally positive. The company has received a consensus rating of Moderate Buy, with an average price target of $57.20, suggesting a potential upside of 62.73%21. Tempus AI scored higher than 61% of companies evaluated by MarketBeat's MarketRank™, and ranked 449th out of 944 stocks in the medical sector22. Tempus AI has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock22. However, it's important to note that 17.78% of the float of Tempus AI has been sold short, indicating potential investor concerns and the possibility of increased volatility22. Tempus's Enterprise Value/Ebitda is -104.03, reflecting its current lack of profitability23.

Key factors to consider when evaluating Tempus AI stock include:

Growth potential: Tempus operates in a rapidly growing market with significant potential for future expansion. The increasing adoption of precision medicine and the growing demand for AI-powered healthcare solutions provide a favorable environment for Tempus's growth.

Financial performance: While not yet profitable, Tempus has demonstrated strong revenue growth. The company's ability to maintain this growth trajectory and achieve profitability will be crucial for its long-term success.

Competitive landscape: The precision medicine market is competitive, but Tempus has a strong platform and a differentiated offering. Its comprehensive data analysis capabilities, advanced AI algorithms, and focus on innovation give it a competitive edge.

Acquisition of Ambry Genetics: The acquisition of Ambry Genetics is expected to expand Tempus's testing capabilities and contribute to its growth. This strategic move strengthens Tempus's position in the precision medicine market and provides access to new markets and customer segments.

Valuation: Tempus's current valuation may be considered high relative to some peers, but its growth prospects and market position justify the premium. However, investors should carefully consider the potential concerns regarding Tempus's valuation relative to its peers, with shares sitting at 12.5 times '25 sales compared to NTRA at 9.4 and GH at 4.623.

Overall, Tempus AI stock presents an interesting investment opportunity for those seeking exposure to the growing precision medicine market. However, investors should carefully weigh the company's growth potential, financial performance, competitive landscape, and potential risks before making an investment decision.

Conclusion

Tempus AI is a leading player in the rapidly growing precision medicine market. The company's AI-driven platform, comprehensive data analysis capabilities, and focus on innovation position it for continued growth. While profitability remains a challenge, Tempus's strong revenue growth, strategic acquisitions, and commitment to research and development suggest a promising future.

The company's recent developments, such as the national launch of the xT CDx test, the new GenAI capabilities in Tempus One, and the acquisition of Ambry Genetics, demonstrate its dedication to advancing precision medicine through AI and data analytics. However, investors should carefully consider the potential risks and challenges, including data privacy concerns, competition, regulatory changes, and the company's financial performance.

Overall, Tempus AI presents a compelling investment opportunity for those seeking exposure to this transformative sector. By carefully evaluating the company's strengths, weaknesses, opportunities, and threats, investors can make informed decisions about whether Tempus AI aligns with their investment goals and risk tolerance.

Works cited

1. Precision medicine company Tempus AI aims to raise $400M in IPO - Fierce Healthcare, accessed January 21, 2025, https://www.fiercehealthcare.com/health-tech/precision-medicine-company-tempus-ai-files-go-public

2. Tempus AI - Vivli, accessed January 21, 2025, https://vivli.org/ourmember/tempus/

3. Transforming Healthcare with Tempus AI: A Comprehensive Overview - HyScaler, accessed January 21, 2025, https://hyscaler.com/insights/tempus-ai-powered-precision-medicine/

4. www.stocktitan.net, accessed January 21, 2025, https://www.stocktitan.net/news/TEM/#:~:text=Tempus%20AI%20(NASDAQ%3A%20TEM),claims%20for%20colorectal%20cancer%20patients.

5. Tempus AI's Bradley Keywell sells $33.1 million in stock - Investing.com, accessed January 21, 2025, https://www.investing.com/news/insider-trading-news/tempus-ais-bradley-keywell-sells-331-million-in-stock-93CH-3819788

6. JPM25, Day 2: News from Nvidia, Tempus AI and Health Catalyst; A look at Children's Health Dallas' expansion plans | Fierce Healthcare, accessed January 21, 2025, https://www.fiercehealthcare.com/providers/jpm25-day-2-healthcare-conference-draws-protesters-news-nvidia-tempus-ai-and-health

7. Tempus AI Stock Plunges 28.9% in Three Months: What's Next? | Nasdaq, accessed January 21, 2025, https://www.nasdaq.com/articles/tempus-ai-stock-plunges-289-three-months-whats-next

8. News Releases - Investor Relations | Tempus AI, accessed January 21, 2025, https://investors.tempus.com/news-events/news-releases/

9. Tempus Stock Price, Funding, Valuation, Revenue & Financial Statements - CB Insights, accessed January 21, 2025, https://www.cbinsights.com/company/tempus/financials

10. Tempus AI Company Profile 2025: Stock Performance & Earnings | PitchBook, accessed January 21, 2025, https://pitchbook.com/profiles/company/164234-62

11. Eric Lefkofsky - Wikipedia, accessed January 21, 2025, https://en.wikipedia.org/wiki/Eric_Lefkofsky

12. Board of Directors - Investor Relations | Tempus AI, accessed January 21, 2025, https://investors.tempus.com/corporate-governance/board-of-directors/

13. Our History - Tempus, accessed January 21, 2025, https://www.tempus.com/about-us/our-history/

14. Our Team | Tempus, accessed January 21, 2025, https://www.tempus.com/about-us/our-team/

15. Tempus AI shares jump 9% in stock market debut as IPO priced at over $6B valuation, accessed January 21, 2025, https://www.fiercehealthcare.com/health-tech/tempus-ai-shares-jump-15-stock-market-debut-ipo-priced-over-6b-valuation

16. Tempus AI: A Potential Double-Bagger After Recent Pullback - MarketBeat, accessed January 21, 2025, https://www.marketbeat.com/originals/tempus-ai-a-potential-double-bagger-after-recent-pullback/

17. Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics, accessed January 21, 2025, https://www.tempus.com/news/tempus-reports-third-quarter-2024-results-and-agreement-to-acquire-ambry-genetics/

18. Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results - Stock Titan, accessed January 21, 2025, https://www.stocktitan.net/news/TEM/tempus-announces-preliminary-fourth-quarter-and-full-year-2024-6td3j12weehd.html

19. Tempus AI, Inc. SEC 10-Q Report - TradingView, accessed January 21, 2025, https://www.tradingview.com/news/tradingview:9416dd123f743:0-tempus-ai-inc-sec-10-q-report/

20. Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2, accessed January 21, 2025, https://www.tempus.com/news/tempus-next-launches-new-algorithm-to-close-care-gaps-in-guideline-directed-ihc-testing-starting-with-her2/

21. Tempus AI, Inc (TEM) Stock Forecast & Price Targets - Stock Analysis, accessed January 21, 2025, https://stockanalysis.com/stocks/tem/forecast/

22. Tempus AI (TEM) Stock Price, News & Analysis - MarketBeat, accessed January 21, 2025, https://www.marketbeat.com/stocks/NASDAQ/TEM/

23. Tempus AI, Inc. Class A (TEM) Stock Price, Quote, News & Analysis - TipRanks, accessed January 21, 2025, https://www.tipranks.com/stocks/tem